skip to content
Primary navigation


Drug - Cometriq™ (cabozantinib) [Exelixis, Inc.]

March 2014

Therapeutic area - Medullary thyroid cancer

Approval criteria

Diagnosis of progressive, metastatic medullary thyroid cancer (MTC)

Background information

Cometriq (cabozanitinib) is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).The recommended daily dose of COMETRIQ is 140 mg (one 80-mg and three 20-mg capsules). Do not administer COMETRIQ with food. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking COMETRIQ. Continue treatment until disease progression or unacceptable toxicity occurs.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top